Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PK and Cytokines in Retinal Diseases
NCT02067013Phase 2Unknown
- Sponsor
- California Retina Consultants
- Start
- Jul 2015
- Primary completion
- Jul 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in proliferative diabetic retinopathy (PDR), neovascular glaucoma (NVG), Age-related macular degeneration (AMD), sponsored by California Retina Consultants. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)neovascular glaucoma (NVG)Age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02067013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067013.